Report Detail
Implantable Cardiac Rhythm Management Device Markets, December 2016
In 2015, the global market for implantable cardiac rhythm management (CRM) devices was valued at $10.2bn. The overall market, which includes cardiac resynchronization therapy, implantable cardioverter defibrillator, and pacemaker systems, is forecast to expand at a moderate compound annual growth rate of 4.8% and reaching an estimated $13.5bn in unit sales. Sales attributable to ICDs accounted for approximately 44.5% of total product sales in 2015. Pacemaker unit sales accounted for the second largest share of total implantable cardiac rhythm management system sales in 2015, with an estimated market share of 32.7%. Sales of CRT systems accounted for approximately 21.7% of total implantable cardiac rhythm management device sales in 2015. The primary factors supporting market growth are demographic and epidemiological. The expansion of the elderly demographic (age 65+) throughout the world will help to drive unit sales of implantable CRM devices. The prevalence of cardiovascular diseases, including arrhythmia and heart failure, will also increase as the elderly demographic expands as a result of individuals over the age of 65 years being at increased risk of developing cardiovascular disease(s).
Topics covered by this report include:
· implantable cardiac rhythm management devices used in the treatment of arrhythmia and select heart failure patients
· global market forecasts for 2015 through 2021
· overview of innovative technology and its impact on current markets
· major trends in global healthcare systems
· discussion of factors promoting and inhibiting growth in CRT, ICD, and pacemaker markets
· estimated revenues and market shares for major competitors in the implantable cardiac rhythm management device markets